We report the first documented case of pancreatic metastasis from a gastrointestinal stromal tumor of the stomach. A 42-year-old Japanese man presented with severe abdominal discomfort. Computed tomography of the abdomen showed a huge heterogeneous mass consisting of cystic and solid components in the left upper abdomen. 
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract but are rarely malignant tumors of the digestive tract, accounting for 0.1% to 3.0% of all gastrointestinal neoplasms 1 5 . Gastric GISTs metastisize most often to the liver and peritoneum but rarely to the pancreas, but a solitary pancreatic metastasis is extremely difficult to differentiate from a primary pancreatic GIST. To our knowledge, surgical resection of a solitary pancreatic metastasis from a GIST has not previously been reported. We describe the first documented case of pancreatic metastasis from a GIST of the stomach.
Report of a Case
A 42-year-old Japanese man was admitted to our hospital because of severe abdominal discomfort. His medical and family histories were unremarkable. On physical examination, a huge, elastic, hard mass was palpable in the left hypochondriac region. The results of laboratory tests were within normal ranges.
Double-contrast barium gastrography showed a welldemarcated filling defect in the greater curvature of the gastric body (Fig. 1a) . Computed tomography of the abdomen with intravenous contrast material revealed a huge heterogeneous mass, approximately 15 cm in greatest diameter, containing cystic and solid components in the left upper quadrant of the abdomen. The mass compressed the spleen and the pancreas (Fig. 1b) . Positron emission tomography revealed high uptake of 18 F- propria in the body of the stomach. We strongly suspected that the tumor was a primary GIST of the stomach.
To eliminate the severe symptoms of abdominal full- (Fig. 3b, c) and negative for α-smooth muscle actin and S-100 protein. These pathological features were consistent with those of the GIST of the stomach. The pan- creatic tumor also showed similar spindle cells after being stained with hematoxylin and eosin and was well circumscribed and surrounded by normal pancreatic parenchyma (Fig. 4a, b) . The pancreatic tumor was positive for both CD34 and CD117/KIT (Fig. 4c, d ) and was negative for Wilms' tumor 1, cytokeratin, and pancreatic endocrine markers, such as glucagon, insulin, gastrin, and somatostatin.
So that molecular biological examinations could be performed for differential diagnosis, the specific cells The mutation was absent from uninvolved tissue of the patient (Fig. 5a, b, c) . The gene sequencing analysis revealed that both the gastric and pancreatic tumor cells possessed an identical somatic mutation.
The postoperative course was uneventful. Postoperative adjuvant chemotherapy (imatinib mesylate, 400 mg/ 
Discussion
The GISTs are known for their tendency to metastasize by way of both intraperitoneal dissemination and hematogenous routes 6, 7 . The most common hematogenous metastatic site of GISTs is the liver 8 . In contrast, the pancreas is not a common site of metastasis from a GIST of the stomach. We found no previously reported case of GIST metastatic to the pancreas in a MEDLINE search with the key words "gastrointestinal stromal tumor," "pancreatic metastasis," and "pancreas metastasis."
Metastatic tumors account for less than 2% of all pancreatic malignancies. The most common primary origins of metastases to the pancreas are renal cell carcinoma (62.6%); carcinomas of the colon (6.2%), lung (4%), and ovary (4.7%); sarcoma (7.2%); and melanoma of the skin (4%) 9, 10 . However, a previous study has found that at autopsy the most common primary tumor site of metastases to the pancreas is the stomach 11 . In 2014 a retrospective study of 22 patients found that the malignancy most commonly metastasizing to the pancreas was gastric carcinoma 12 . Therefore, gastric malignancies may metastasize to the pancreas more frequently than previously thought.
Histopathological examination of the gastric and pan- Local recurrence and distant metastases have been reported to develop in more than 30% of patients with high-risk GIST despite apparently complete resection 16 .
Most recurrences or metastases occurring after resection with a R0 margin of a high-risk GIST appear within 3 years after primary surgery. Adjuvant therapy with imatinib mesylate, a specific molecular inhibitor, is beneficial after the primary GIST is resected. Three years of adjuvant treatment with imatinib mesylate has been shown to improve recurrence-free survival and overall survival in patients with high-risk GISTs 17 . However, tumor sensitivity to imatinib has been reported to differ according to the location of the mutation 18 . The GISTs with exon 11 mutations of KIT are more than 10 times as sensitive to imatinib than are GISTs with mutations in other exons 19 . Identification of the causative mutation before starting imatinib treatment is thus considered clinically and economically beneficial in patients with GIST 20 . In our patient, both the gastric and pancreatic GISTs had mutations of exon 11 in the KIT gene. The tumors were therefore expected to be sensitive to imatinib treatment.
The patient has shown no sign of recurrence or disease progression for more than 4 years after surgery and continues to receive adjuvant treatment with imatinib.
In conclusion, we have reported an extremely rare case of gastric GIST with synchronous pancreatic metastasis that successfully responded to multimodality therapy.
Our findings may be helpful for determining a multimodality treatment strategy and for developing new treatment options for a case of GIST with such unusual metastases.
